Related Blog Posts from the Wikinvest Wire

Abbott Laboratories (ABT)   Subscribe to Abbott Laboratories (ABT) content from the Wikinvest Wire
 » Back to Abbott Laborato… (NYSE:ABT) Stock Page

  

3/28/14Abbott Laboratories (NYSE:ABT) – Abbott Announces FDA Approval of Its Supera® Stent to Treat P... (Jutia Group)

[PR Newswire] - ABBOTT PARK, Ill., March 28, 2014 /PRNewswire/ -- Abbott today announced that its Supera® Peripheral Stent System has received U.S. Food and Drug Administration (FDA) approval to treat people with blocked blood vessels in the upper leg caused by peripheral artery disease (PAD). PAD occurs when fat and cholesterol buildup causes [...]

2/5/14Abbott Laboratories (NYSE:ABT) | Abbott Labs Sued by Five Men Claiming Androgel Injuries (Jutia Group)

[at Bloomberg] - Abbott Laboratories (ABT) and AbbVie Inc., the company it spun off last year, hid the dangers of using the testosterone replacement drug AndroGel, five men claimed in lawsuits. Their complaints, filed ... Read more on this. Abbott Laboratories (ABT), with a current market cap of $56.31B, started trading this morning [...]

1/30/14Company Update: Abbott Laboratories (NYSE:ABT) – Abbott to close Puerto Rico manufacturing plant (Jutia Group)

[AP] - Abbott Laboratories is closing one of its manufacturing plants in the Puerto Rico town of Barceloneta next year, delivering another blow to the U.S. territory's once-thriving pharmaceutical sector, officials ... Read more on this. Abbott Laboratories (ABT), with a current value of $56.48B, started the session at $36.20.   [...]

1/24/14Abbott Laboratories (NYSE:ABT) – Abbott’s Earnings Increase 22% Year Over Year, But Is It A Buy? (Jutia Group)

[at Seeking Alpha] - Abbott Laboratories ( ABT ) is engaged in the discovery, development, manufacture and sale of a portfolio of science-based healthcare products, which operates in four segments: Diagnostics, Medical Devices, ... Read more on this. Abbott Laboratories (ABT), valued at $56.54B, opened at $37.20.   Looking at [...]

1/22/14Abbott Laboratories (NYSE:ABT) | Abbott Reports Fourth-Quarter and Full-Year 2013 Results (Jutia Group)

[PR Newswire] - ABBOTT PARK, Ill., Jan. 22, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2013. Ongoing diluted EPS was $0.58 in the fourth quarter and ... Read more on this. Abbott Laboratories (ABT), currently valued at $58.88B, ended session yesterday at $39.12. [...]

1/21/14Company Update: Abbott Laboratories (NYSE:ABT) – GSK gets new trial against Abbott over gay jur... (Jutia Group)

[Reuters] - GlaxoSmithKline Plc deserves a new trial against Abbott Laboratories because Abbott impermissibly excluded a potential juror based on his sexual orientation, a federal appeals court ruled on Tuesday. GSK ... Read more on this. Abbott Laboratories (ABT), currently valued at $60.56B, started trading this morning at $39.53.   [...]

1/8/14Abbott Laboratories (NYSE:ABT) – 125 Years Of Healthcare Innovation and Still Growing (Jutia Group)

[at Motley Fool] - Now that the dust surrounding Abbott Laboratories has settled from the AbbVie spinoff, it’s much easier to get a clear picture of the company’s growth opportunities. Here are some factors to look out for ... Read more on this. Abbott Laboratories (ABT), with a current market cap of $60.44B, [...]

1/7/14Company Update – Abbott Laboratories (NYSE:ABT) – Will Abbott Perform Better In 2014? (Jutia Group)

[at Seeking Alpha] - By the end of the third quarter of 2013 Abbott Laboratories ( ABT ) increased its dividend payout for the 41st consecutive year. This marks the 359th consecutive quarterly dividend to be paid out by Abbott ... Read more on this. Abbott Laboratories (ABT), currently valued at $60.07B, started [...]

1/6/14Company Update – Abbott Laboratories (NYSE:ABT) – Abbott Hosts Conference Call for Fourth-Qua... (Jutia Group)

[PR Newswire] - ABBOTT PARK, Ill., Jan. 6, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter and full-year 2013 financial results on Wednesday, Jan. 22, 2014, before the market opens. The announcement ... Read more on this. Abbott Laboratories (ABT), with a current market cap of $60.63B, began trading this morning [...]

12/17/13Stock Update: Abbott Laboratories (NYSE:ABT) – A Space Age View into Human Vision: Abbott’s i... (Jutia Group)

[PR Newswire] - ABBOTT PARK, Ill., Dec. 17, 2013 /PRNewswire/ -- With the introduction of Abbott's iDesign Dx system, U.S. ophthalmologists now have a diagnostic tool that can capture five optical measurements in one three-second scan to determine the patient's visual abnormalities. Obtaining these measurements in one three-second scan enables ophthalmologists to screen patients [...]

12/12/13Abbott Laboratories (NYSE:ABT) | ModernGraham Valuation Of Abbott Laboratories (Jutia Group)

[at Seeking Alpha] - Here is a look at how Abbott Laboratories ( ABT ) fares in ModernGraham's opinion, based on an updated and modernized version of Benjamin Graham's requirements of defensive and enterprising investors from ... Read more on this. Abbott Laboratories (ABT), with a current market cap of $56.34B, started trading [...]

12/11/13Company Update – Abbott Laboratories (NYSE:ABT) – Abbott Laboratories Raised Its Dividend 57%... (Jutia Group)

[at Seeking Alpha] - The last time I wrote about Abbott Laboratories ( ABT ) I did not buy any more shares stating that I thought the stock had moved up too far up too quickly. The stock is down 2.65% since last writing the ... Read more on this. Abbott Laboratories (ABT), [...]

11/26/13Company Update – Abbott Laboratories (NYSE:ABT) – Will Google soon pass Exxon in market value? (Jutia Group)

[at CNNMoney.com] - The opinions expressed in this commentary are solely those of Paul R. La Monica. Other than Time Warner, the parent of CNNMoney, Abbott Laboratories and AbbVie, La Monica does not own positions in any ... Read more on this. Abbott Laboratories (ABT), currently valued at $58.99B, started trading this morning [...]

11/21/13AbbVie Inc. (NYSE:ABBV) ~ New Research And Competition Could Hurt AbbVie’s Other Blockbuster (Jutia Group)

[at Seeking Alpha] - Investors of AbbVie ( ABBV ) know that its stock price is mostly driven by the success of Humira, the best selling medication in the world. However AbbVie's second best selling medication is a testosterone ... Read more on this. AbbVie Inc. (ABBV), with a current value of $76.97B, [...]

11/18/13Stock Update: Abbott Laboratories (NYSE:ABT) – 1 Biotech Buy-and-Hold Lesson Wall Street Wants ... (Jutia Group)

[at Motley Fool] - Wall Street panicked at the end of 2000 when Abbott Labs announced it was acquiring the pharmaceutical business of BASF. Shares sank 7.1% the next trading day on fears of dilution and a lack of execution. ... Read more on this. Abbott Laboratories (ABT), currently valued at $58.69B, began [...]

11/14/13Company Update: Abbott Laboratories (NYSE:ABT) – Experience ″A Day in the Life″ of an Insul... (Jutia Group)

[PR Newswire] - ABBOTT PARK, Ill., Nov. 14, 2013 /PRNewswire/ -- In honor of World Diabetes Day, Abbott has created an interactive infographic to help raise awareness about what life can be like for an insulin-using patient who has diabetes. Many people with diabetes are prescribed insulin, either because their bodies do not produce [...]

11/4/13Company Update – Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Vs. Abbvie In Potent... (Jutia Group)

[at Seeking Alpha] - Bristol-Myers Squibb ( BMY )'s new experimental drug for rheumatoid arthritis (RA) caused excitement at a conference in October. It appears that the drug clazakizumab is as effective as AbbVie ( ABBV )'s ... Read more on this. Bristol-Myers Squibb Company (BMY), currently valued at $87.31B, started trading this [...]

11/4/13AbbVie Inc. (NYSE:ABBV) | Bristol-Myers Vs. Abbvie In Potential Humira Rivalry (Jutia Group)

[at Seeking Alpha] - Bristol-Myers Squibb ( BMY )'s new experimental drug for rheumatoid arthritis (RA) caused excitement at a conference in October. It appears that the drug clazakizumab is as effective as AbbVie ( ABBV )'s ... Read more on this. AbbVie Inc. (ABBV), valued at $76.78B, opened this morning at $49.19. [...]

11/4/13Abbott Laboratories (NYSE:ABT) – Abbott Labs Lacks Diversification (Jutia Group)

[at TheStreet] - Given that shares of Abbott Labs It's true that Abbott's lack of revenue growth didn't give me that "warm and fuzzy" feeling about its competitive position against the likes of Roche "I believe the only way to justify buying this stock -- even on this recent pullback -- is for management [...]

10/29/13Abbott Laboratories (NYSE:ABT) – Who’s cutting the cord? Cable stocks soaring (Jutia Group)

[at CNNMoney.com] - The opinions expressed in this commentary are solely those of Paul R. La Monica. Other than Time Warner, the parent of CNNMoney, Abbott Laboratories and AbbVie, La Monica does not own positions in any ... Read more on this. Abbott Laboratories (ABT), valued at $58.08B, opened this morning at $37.30. During [...]

10/25/13Abbott Laboratories (NYSE:ABT) – AbbVie Profit Beats Estimates as Sales of Humira Increase (Jutia Group)

[at Bloomberg] - AbbVie Inc., the drugmaker that split from Abbott Laboratories in January, reported third- quarter earnings that beat analysts’ estimates as sales of its top drug Humira rose. The company raised the bottom ... Read more on this. Abbott Laboratories (ABT), currently valued at $57.88B, started trading this morning at $37.24. Shares [...]

8/21/13(ABT) Abbott Laboratories Announces CE Mark for Xpedition 48 Stent System (Stock Blog Hub)

Abbott Laboratories (ABT) recently announced that it received CE Mark in Europe for its drug eluting stent – Xience Xpedition 48 Everolimus Eluting Coronary Stent System. Xience Xpedition 48 is the latest addition to Abbott Labs’ Xience drug-eluting stent franchise. The product is designed to enable treatment for very long blockages in the vessels that supply blood [...]

5/2/13(ABT) Abbott Laboratories Launches Automated Solution (Stock Blog Hub)

Abbott Laboratories (ABT) recently announced that the company has launched ACCELERATOR a3600 – its next-generation track system to increase efficiency in laboratories. A laboratory automation track system, ACCELERATOR a3600 enables processing for up to 3,600 samples per hour along with handling multiple tube sizes and types simultaneously. Moreover, this system automates routine, manual tasks which in turn [...]

2/18/13(ABT) AbbVie Provides 2013 Outlook (Stock Blog Hub)

AbbVie (ABBV) recently confirmed its sales figures for 2012 and provided guidance for 2013 as an independent company. AbbVie came into existence earlier this year following its separation from Abbott Laboratories (ABT). AbbVie said that excluding the negative impact of currency fluctuation (3%), pharmaceutical segment revenues grew more than 8% in the fourth quarter of 2012 [...]

2/1/13Should dividend investors hold on to Abbott (ABT) and Abbvie (ABBV) following the split? (Dividend Growth Investor)

I have been a shareholder of Abbott Laboratories for several years. I liked the fact that the company was constantly undervalued, and also managed to offer a very attractive yield plus an above average dividend growth. My last addition to my position occurred in the final weeks of 2012. In my last analysis of the stock, I was bullish on its business going forward. On January 1, 2013, Abbott Laboratories split into two companies, one which retained its name Abbott Laboratories (ABT), and...

1/25/13Reconsidering Abbott Labs (ABT) And AbbVie (ABBV) (The DIV-Net)

Abbott Laboratories: A company I loved  At the beginning of this year, Abbott Laboratories (ABT) completed the spin-off of its branded pharmaceutical business. This business is now a separate publicly traded company, calling itself AbbVie Inc. (ABBV). I have long been a fan of Abbott Laboratories as a diversified health care company with operations in medical devices, diagnostics, branded pharmaceuticals and nutrition among other businesses. It's been in business since 1888 and it's been...

1/24/13Abbott Dividend Stock Analysis (The DIV-Net)

I have been a shareholder of Abbott Laboratories for several years. I liked the fact that the company was constantly undervalued, and also managed to offer a very attractive yield plus an above average dividend growth. My last addition to my position occurred in the final weeks of 2012. In my last analysis of the stock, I was bullish on its business going forward. On January 1, 2013, Abbott Laboratories split into two companies, one which retained its name Abbott Laboratories...

1/15/13(ABT) Abbott Laboratories’ ABSORB in Phase III Trial (Stock Blog Hub)

Abbott Laboratories (ABT) recently announced that its Absorb Bioresorbable Vascular Scaffold (BVS) device has moved into a phase III study, ABSORB III, in the US. The randomized, controlled study will enroll 2,250 patients and will compare Absorb BVS’s performance to the company's Xience drug eluting stents. We note that Absorb is available in Europe and some [...]

1/3/13Abbot Labs Jumps On FDA Approval For Heart Stent (Stock Wizard)

Shares of Abbott Laboratories (NYSE: ABT) surged as much as 3% on Thursday after the company announced that the XIENCE Xpedition Everolimus Eluting Coronary Stent System received U.S. Food and Drug... [[ This is a content summary only. Visit my website for full links, other content, and more! ]]

12/21/12Abbott Laboratories: Quality Dividend Aristocrat for Long Term Dividends (Dividend Growth Investor)

Abbott Laboratories (ABT) engages in the discovery, development, manufacture, and sale of health care products worldwide. This dividend champion has boosted distributions for 40 years in a row. The company’s last dividend increase was in February 2012 when the Board of Directors approved a 6.30% increase to 51 cents/share. The company’s peer group includes Johnson & Johnson (JNJ), Bristol Myers Squibb (BMY) and Merck (MRK). Over the past decade this dividend growth stock has...

12/17/12Stock Analysis: Abbott Laboratories (ABT) (The DIV-Net)

Linked here is a detailed quantitative analysis of Abbott Laboratories (ABT). Below are some highlights from the above linked analysis: Company Description: Abbott Laboratories is a diversified life science company that is planning to split into two publicly traded companies, one in diversified medical products and the other in research-based pharmaceuticals. Fair Value: In calculating fair value, I consider the NPV MMA Differential Fair Value along with these four calculations of fair...

12/14/12Abbott Laboratories Stock Analysis (The DIV-Net)

Abbott Laboratories (ABT) engages in the discovery, development, manufacture, and sale of health care products worldwide. This dividend champion has boosted distributions for 40 years in a row. The company’s last dividend increase was in February 2012 when the Board of Directors approved a 6.30% increase to 51 cents/share. The company’s peer group includes Johnson & Johnson (JNJ), Bristol Myers Squibb (BMY) and Merck (MRK). Over the past decade this dividend growth stock has delivered...

10/8/12(ABT) Abbott Laboratories- Astellas Pharma Global Development Collaborate (Stock Blog Hub)

Abbott Laboratories (ABT) recently announced that it is collaborating with Astellas Pharma Global Development for a phase III study being conducted with ASP0113 (TransVax). TransVax, a vaccine in-licensed by Astellas from Vical Inc. (VICL), is being developed for the prevention of cytomegalovirus (CMV) reactivation in transplant patients. Under the collaboration, patients will be monitored for CMV [...]

9/27/12Everybody hates HP (Penny Stock DD)

The opinions expressed in this commentary are solely those of Paul R. La Monica. Other than Time Warner, the parent of CNNMoney, and Abbott Laboratories, La Monica does not own positions in any individual stocks. When your stock is trading at just 4 times earnings estimates for the next year, you'd think that [...]

6/11/12Stock Analysis: Abbott Laboratories (ABT) (The DIV-Net)

Linked here is a detailed quantitative analysis of Abbott Laboratories (ABT). Below are some highlights from the above linked analysis: Company Description: Abbott Laboratories is a diversified life science company that is planning to split into two publicly traded companies, one in diversified medical products and the other in research-based pharmaceuticals. Fair Value: In calculating fair value, I consider the NPV MMA Differential Fair Value along with these four calculations of fair...

6/6/12(BMY) Bristol-Myers Squibb Company Presents Positive Data (Stock Blog Hub)

Bristol-Myers Squibb Company (BMY) recently presented encouraging data from a late-stage study (AMPLE: n=646), which evaluated the efficacy of the subcutaneous formulation of its rheumatoid arthritis (RA) drug Orencia versus Abbott Laboratories’ (ABT) anti-inflammatory drug Humira. The data was presented at the European League Against Rheumatism (EULAR) annual European congress of rheumatology. The randomized, investigator-blinded multinational [...]

4/28/12(STJ) St. Jude Medical Build on Alliance with Abbott Laboratories (Stock Blog Hub)

St. Jude Medical Inc. (STJ) recently disclosed its decision to build on its mutual agreement with Abbott Laboratories (ABT) by revealing the long-term Choice Alliance joint venture. This initiative provides St. Jude Medical the opportunity to incorporate Abbott's drug-eluting stents with its cardiovascular, cardiac rhythm management and electrophysiology offerings. Both companies have agreed to endorse each [...]

4/18/12Abbott Beats Estimates, Lifts Forecast (Penny Stock DD)

Healthcare products maker Abbott Laboratories (ABT: News ) on Wednesday reported a 44 percent surge in profit for the first quarter, helped by higher sales of its drugs and nutritional products. Both revenues and ongoing earnings per share topped analysts' expectations. Buoyed by the results, Abbott raised its earnings outlook [...]

4/13/12Abbott Laboratories is Cheaper than you think (Dividend Growth Investor)

In a previous article, I discussed how dividend investors should analyze the earnings of each company they own in detail, in order to obtain an understanding behind the real valuation behind the business. I discussed how AT&T (T) and Coca-Cola (KO) appeared cheaper than usual. Today, I will discuss another example of a situation, where I had to dig deeper, before obtaining the full picture behind Abbott Lab’s valuation. I have been a shareholder of Abbott Labs (ABT) for many years. Just...

4/6/12Stock Analysis of Abbott Laboratories (ABT) (The DIV-Net)

In a previous article, I discussed how dividend investors should analyze the earnings of each company they own in detail, in order to obtain an understanding behind the real valuation behind the business. I discussed how AT&T (T) and Coca-Cola (KO) appeared cheaper than usual. Today, I will discuss another example of a situation, where I had to dig deeper, before obtaining the full picture behind Abbott Lab’s valuation. I have been a shareholder of Abbott Labs (ABT) for many years. Just...

3/21/12This Great-Performing Stock Just Got a Lot Better (Jutia Group)

Not long after I wrote about this big health care firm in December 2010, this stock began a nice hot streak. It's now up 31% in the past 12 months, compared with a 14% gain for the S&P 500 during the same time. This is undoubtedly a great-performing stock. But when I first suggested investing in [...]

3/3/12Abbot Laboratories’ share price (The Market Financial)

Here we model the evolution of Abbot Laboratories’ (NYSE: ABT) stock price since July 2003. Abbot is a company from healthcare sector of the S&P 500 index. We model a share price decomposing it into a weighted sum of two consumer price indices....

2/20/12Upward Movements On Abbott Laboratories (NYSE:ABT) Stock Picks (Penny Stock DD)

Introduction: Abbott Laboratories (NYSE:ABT)Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. The company offers adult and pediatric pharmaceuticals for rheumatoid and psoriatic arthritis, ankylosing spondylitis, psoriasis, and Crohn's disease; dyslipidemia; HIV infection; prostate cancer, endometriosis and central precocious puberty, and anemia caused by uterine fibroids; respiratory syncytial virus; adult [...]

2/17/12Abbott Laboratories (ABT): An attractively valued dividend aristocrat (Dividend Growth Investor)

Abbott Laboratories (ABT) engages in the discovery, development, manufacture, and sale of health care products worldwide. It operates in four segments: Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The company is a dividend aristocrat which has increased distributions for 39 years in a row. The most recent dividend increase was in February 2011, when the Board of Directors approved a 9.10% increase in the quarterly dividend to 48 cents/share....

2/8/12Cash-Secured Puts: Keep the Cash Flowing – Even After You've Sold the Stock (Money Morning)

In January, I told you how you can double or even triple your yield by selling "covered" calls on your dividend stocks. While this is a safe and highly effective strategy, selling covered calls does have a drawback - of a sort. If the stock you're holding rises in price before the calls you sold expire, you could be forced to sell the shares at the option's designated strike price. This isn't likely to be a huge problem since you'll be selling your stock at a profit. The...

11/28/11Stock Analysis: Abbott Laboratories (ABT) (The DIV-Net)

Linked here is a detailed quantitative analysis of Abbott Laboratories (ABT). Below are some highlights from the above linked analysis: Company Description: Abbott Laboratories is a diversified life science company that is a leading maker of drugs, nutritional products, diabetes monitoring devices, and diagnostics. In mid-October 2011, Abbott announced plans to split the company. Fair Value: In calculating fair value, I consider the NPV MMA Differential Fair Value along with these...

11/25/11Abbott Labs Breakup and Moat (Value Stock Guide)

Abbot Labs announced earlier that it is splitting up into two companies. It will spin off its proprietary drug business by the end of 2012 and retain the rest of its businesses under the Abbott name. At $82 Billion in market value, Abbott is too large of a company to attract my interest, but whenever [...]

11/8/11Checking In: Another Income Play (EQIN, VIG, VTV, ABT) (Wall Street Sector Selector)

Give ETF issuers this much credit: In 2011,

10/31/11Abbott Laboratories (NYSE:ABT) Delivers the 6th Highest EPS Growth Rate in is Industry (Penny Stock DD)

Company Profile Abbott Laboratories (NYSE:ABT) was incorporated in 1888 and is engaged in discovery, development, manufacturing and selling of health care products around the globe. Based in Abbot Park, Illinois, the company offers adult and pediatric pharmaceuticals for rheumatoid and psoriatic arthritis, ankylosing spondylitis, psoriasis and Crohn’s disease, HIV infection, dyslipidemia, prostate cancer, endometriosis, anemia, hypothyroidism [...]

10/19/11Abbott Laboratories spins off drug business, retains low-risk health care products (Penny Stock DD)

 Abbott Laboratories, long known for selling a mix of drugs, medical implants and baby formula, said Wednesday it will spin off its branded drug business and become two separate companies with more distinct identities. The split-up frees Abbott from the risks and obligations of developing innovative pharmaceutical drugs, leaving the company with a more predictable business [...]


Your blog posts can appear here by joining the Wikinvest Wire
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki